|
KMID : 0948920020010020079
|
|
Clinical Pain
2002 Volume.1 No. 2 p.79 ~ p.88
|
|
|
COX-2 Inhibitor
|
|
Kim Mi-Jung
|
|
|
Abstract
|
|
|
|
Cyclooxygenase (COX) is the key enzyme in the synthesis of prostaglandins from arachidonic acid during inflammatory cascade in the cell membrane. The 2 isoforms of COX are recently discovered and called COX-1 and COX-2. COX-1 is a constitutive form and COX-2 is induced in response to specific stimuli. This recent discovery of two isoenzymes enables the introduction of a new generation of non-steroidal anti-inflammatory drugs (NSAIDs) that selectively targets the cyclooxygenase 2 (COX-2). They are called as ’selective COX-2 inhibitor’ and main advantage of those are decreased gastrointestinal toxicity compared with conventional NSAIDs. For the patients with musculoskeletal disorders, conventional NSAIDs are a mainstay of clinical care, but NSAID-induced gastrointestinal complications have been a troublesome limitiation to use it, especially in long term users. COX-2 inhibitors have a potential to prevent colorectal malignancies especially associated with familial background. But also, they might have potential limitations because they do not inhibit platelet aggregation and could adversely affect the hemostatic balance and favor thrombosis.
|
|
|
KEYWORD
|
|
|
Cyclooxygenase (COX), COX-1, COC-2, Nonsteroidal anti-inflammatory drugs (NSAIDs)
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|